NanoSight Acquired by Malvern Instruments

News   Sep 30, 2013

 
NanoSight Acquired by Malvern Instruments
 
 
 
 

RELATED ARTICLES

CRISPR Reveals New Targets for Promising Cancer Drugs

News

Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.

READ MORE

Cell Recycling System Offers Therapeutic Entry Point for Rare Disease Treatment

News

Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).

READ MORE

Study Indicates 75% of Human Genome is Non-functional

News

An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE